In the absence of ligands, the nuclear receptor PPAR␤/␦ recruits the NCOR and SMRT corepressors, which form complexes with HDAC3, to canonical target genes. Agonistic ligands cause dissociation of corepressors and enable enhanced transcription. Vice versa, synthetic inverse agonists augment corepressor recruitment and repression. Both basal repression of the target gene ANGPTL4 and reinforced repression elicited by inverse agonists are partially insensitive to HDAC inhibition. This raises the question how PPAR␤/␦ represses transcription mechanistically. We show that the PPAR␤/␦ this coincides with decreased binding of RNA polymerase II (RNAPII) (15). Agonists alleviate basal repression, and transcription is induced synergistically with other activating stimuli (18, 19) .
INTRODUCTION
PPAR␤/␦ (peroxisome proliferator activated receptor ␤/␦) is a type II nuclear receptor which constitutively binds to DNA as an obligate heterodimer with a retinoid X receptor (RXR). Its target genes function in lipid and glucose metabolism and also in inflammation (1, 2) . In the absence of ligands, the PPAR␤/␦-RXR heterodimer represses its canonical target genes (1) via the recruitment of corepressors (3) such as NCOR (nuclear receptor corepressor)-and SMRT (silencing mediator of retinoid and thyroid hormone receptors)-containing complexes (4) (5) (6) . Both corepressor complexes harbour the catalytic subunit histone deacetylase 3 (HDAC3) (7, 8) , whose activity requires binding to NCOR or SMRT (9) . Several fatty acids and their derivatives act as endogenous PPAR␤/␦ agonists (10) (11) (12) (13) . Agonistic ligands cause dissociation of corepressors from the nuclear receptor at ligand-regulated target genes, while synthetic inverse agonists recently developed in our group lead to enhanced corepressor recruitment (5, (14) (15) (16) ). An important PPAR target gene is ANGPTL4 (angiopoietin-like 4), a regulator of lipid metabolism, angiogenesis, wound healing, and metastasis (15, 17) . Basal repression of ANGPTL4 and augmented repression in the presence of inverse agonists are largely insensitive to trichostatin A (15) , an inhibitor of class I and II HDACs, suggesting an HDAC-independent repression mechanism. Induction of ANGPTL4 transcription by activating stimuli is efficiently suppressed by PPAR␤/␦ inverse agonists, and 
Genetic deletion and stable transfection
Vectors for parallel expression of a guide RNA and the Cas9 nuclease were obtained from Santa Cruz Biotechnology. The sequences targeting the PPARD coding region were TC GTACGATCCGCATGAAGC (i), CCCTGTGCAGCTATCCGTTT (ii) and AACACTCACCGCCGTGTGGC (iii). MDA-MB231-luc2 cells were transfected using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions with the guide/Cas9 expression vectors together with pM-SCVbsd (41) for selection of transfected cells. After 4 h, the cells were supplemented with fresh medium, and blasticidin was added after 30 h at a concentration of 10 g/ml. After 10 days, single cells were seeded using limiting dilution in cell-free medium conditioned by the parental cell line. Wells with more than one colony were terminated. Clones were expanded and screened via RT-qPCR (loss of ANGPTL4 repression by PT-S264) and immunoblotting against PPAR␤/␦. The 2B3 clone was transfected with pWZLneo-ecoR (42) . After 24 h, the cells were selected with 500 g/ml G418 for 14 days.
PPARD expression vectors
The retroviral vector pMSCVbsd (41) was used to clone the PPARD cDNA into the BglII and XhoI sites. Terminal deletions were introduced via polymerase chain reaction (PCR) with specific primers, and the fragment was reinserted into the empty pMSCVbsd vector. Alterations in the cDNA sequence were introduced with site-directed mutagenesis. All plasmid preparations used for retroviral transduction were validated by sequencing of the entire cDNA inserts. Subsequent new plasmid preparations were validated by resequencing. Vectors are available from Addgene.
Retroviral transduction
For production of ecotropic retroviruses, pMSCVbsd-PPARD vectors or the empty vector were transfected into subconfluent NX-eco packaging cells (40) . After 4 h, 7 ml of fresh medium were added. Twenty-four hours later, the supernatant was harvested, centrifuged at 800 × g, and 3 ml aliquots were snap frozen. The NX-eco cells received fresh medium, and a second supernatant was harvested 24 h later. Freshly seeded MDA-MB231-luc2-2B3 cells ectopically expressing the ecotropic receptor were incubated with 2 ml of fresh medium, 3 ml of NX supernatant, and 4 g/ml polybrene for 24 h. Selection was performed with 10 g/ml blasticidin for ten days, and cells were subsequently cultured in the presence of blasticidin.
RNA isolation, cDNA synthesis and quantitative RT-PCR
Total RNA was isolated with the NucleoSpin RNA kit (Macherey&Nagel, no. 740955) according to the manufacturer's instructions; the DNase digestion and desalting steps were omitted. Complementary DNA synthesis was carried out with the iScript cDNA Synthesis Kit (Bio-Rad, no. 170-8891SP) according to the manufacturer's instructions with 500 ng of purified RNA per sample in 20 l. Quantitative PCR analyses were performed in three technical replicates per sample using ABsolute SYBR Green master mix (Thermo Scientific, no. AB-1158B) in a total reaction volume of 10 l in M×3000p and Mx3005 thermocyclers (Agilent). Prior to PCR, cDNA samples were diluted 1:10, and 4.75 l were used per reaction. The RPL27 transcript was used for normalization. RT-qPCR was carried out with primer concentrations of 250 nM each. The primer sequences are available in Supplementary Table S1 . Ct values were normalized to the RPL27 transcript; to retain information about ANGPTL4 expression levels, the mean RPL27 Ct value of all samples in the respective assay was added back where suitable.
Chromatin immunoprecipitation (ChIP)-qPCR
ChIP was essentially performed as described previously (43, 44) . Fixation was performed with 1 % formaldehyde in media for 10 min at room temperature followed by quenching with 125 mM glycin for 5 min. Cells were lysed in buffer L1 ( Supplementary Table S2 .
ChIP-mass spectrometry (ChIP-MS)
Two technical replicates each were performed by Active Motif Epigenetic Services according to a published protocol (45) from the following MDA-MB231-luc2 samples: IgG, PT-S264 treatment (0.3 M); ␣-PPAR␤/␦, PT-S264 treatment (0.3 M); ␣-PPAR␤/␦, L165,041 treatment (1.0 M). The unspecific IgG pool from rabbit was obtained from Sigma-Aldrich (no. I5006), the PPAR␤/␦ antibody from Santa Cruz Biotechnology (sc-7197, rabbit polyclonal). Candidate proteins were filtered with scaffold Viewer 4.8.3 (Proteome Software) according to the following criteria: at least two unique peptides in total and a maximum of two unique peptides each in the negative control replicates (IgG). The protein and the peptide thresholds were each set to 80 %.
RESULTS

PPAR␤/␦ inverse agonists interfere with formation of an initiation complex
PT-S264 is an inverse PPAR␤/␦ agonist with improved repressive properties and stability (16) . We first tested whether it affects initiation complex formation like the previously used inverse agonist ST247 (46) , which reduces RNAPII binding to the ANGPTL4 promoter (15) . TGF␤ is a strong inducer of ANGPTL4 transcription in human cells (18) . Treatment with PT-S264 strongly reduced RNAPII (large subunit RPB1) binding to the ANGPTL4 TSS as shown by scanning ChIP-qPCR using closely spaced primer pairs ( Figure 1A ) both in the presence and in the absence of TGF␤ in Caki-1 cells. We used the 8WG16 antibody, which in our hands detects total RNAPII with superior specificity to other RNAPII antibodies (Supplementary Figure  S1 ). The binding pattern of RNAPII in PT-S264-treated cells is similar to the binding pattern observed in cells treated with the transcription initiation inhibitor triptolide, which however is more effective in reducing RNAPII binding compared to PT-S264 (upper panels of Figure 1A ). In contrast, treatment of the cells with the CDK9 inhibitors DRB and flavopiridol, which interfere with elongation, does not prevent TGF␤-induced RNAPII accumulation at the TSS (blue and green lines in the lower panels of Figure 1A ). This indicates that PT-S264 prevents RNAPII recruitment to the ANGPTL4 promoter in a manner similar to the effect of triptolide. Taken together, these observations show that PT-S264 impinges on transcription initiation of ANGPTL4. Notably, ChIP-qPCR data obtained with antibodies against the RPB1 CTD phosphorylated at serine 5 (initiating RNAPII) or serine 2 (elongating RNAPII) do not support an effect of PT-S264 on serine 2 phosphorylation when taking total RNAPII enrichment into account (Supplementary Figure S1 ), which again implies that the inverse agonist diminishes RNAPII recruitment and furthermore argues against an effect of PT-S264 on RPB1 CTD phosphorylation. We therefore conclude that the formation of an initiation complex is affected by PT-S264.
In order to clarify how PT-S264 interferes with RNAPII recruitment, we performed further experiments with the Caki-1 line. These cells highly express ANGPTL4 (15) and hence allow for ChIP-based detection of GTFs at the endogenous locus. To address which step of initiation complex formation is affected, we measured the occupancy of GTFs at the ANGPTL4 TSS in the presence or in the absence of PT-S264. Binding of TFIIB and RNAPII is reduced upon treatment with PT-S264 compared to the control. However, the occupancy of TFIIA is not altered ( Figure 1B ), suggesting that the repressive mechanism affects the transition from the scaffold complex to the RIC. PIC formation may be impaired too, which cannot be inferred from these data obtained after short-term treatment. The effect of PT-S264 is PPAR-dependent, as TFIIB and RNAPII binding remain unchanged at the TSS of TSC22D3, which is not a PPAR target. In the presence of TGF␤, TFIIB binding to the ANGPTL4 TSS is increased, and this is counteracted by PT-S264 ( Figure 1C ).
The Mediator complex facilitates the rate-limiting step of TFIIB recruitment, and both Mediator and TFIIB are necessary for RNAPII binding in a reconstituted human transcription system (30) as well as in Saccharomyces cerevisiae in vivo (47) . Initial ChIP-qPCR experiments after treatment with the previously used inverse agonist ST247 show that both TFIIH, another GTF present in the scaffold, and MED1 (Mediator subunit 1) bind to the ANGPTL4 TSS after TGF␤ treatment. However, in the presence of the inverse agonist ST247, MED1 recruitment is blocked (Supplementary Figure S2 ); TBP ChIP data were not conclusive and show an enrichment pattern similar to MED1. The TFIIA and TFIIH ChIPs show that inverse agonists do not generally block recruitment of PIC components. This led to the hypothesis that PPAR␤/␦ inverse agonists affect Mediator binding to the promoter. Scanning ChIP-qPCR analyses of Caki-1 cells treated with PT-S264, TGF␤, or both show that PT-S264 counteracts TGF␤-stimulated recruitment of MED1 ( Figure 2A scription (48) (49) (50) . Since the Mediator kinase module is detected at promoters in metazoans (51), we performed additional scanning ChIP across the ANGPTL4 TSS with an antibody against MED13L, a Mediator subunit that resides in the kinase module in the presence of MED26 (52) . Recruitment of MED13L upon stimulation with TGF␤ but not after simultaneous treatment with the inverse agonist PT-S264 ( Figure 2D ) is detected in the same manner as MED1 ( Figure S1 ). At the promotor of PAI1, which is a TGF␤ target gene but not a PPAR target gene, TGF␤-stimulated recruitment of MED1 and MED26 was not impaired by PT-S264 (Supplementary Figure S3 ). Taken together, our data suggest that MED1, MED13L, and MED26 binding occur in a transcriptionally permissive state induced by TGF␤, which is prevented in the presence of PT-S264. We conclude that PPAR␤/␦ inverse agonists perturb transcription initiation at the ANGPTL4 TSS by interfering with TFIIB-RNAPII recruitment to promoterbound GTFs, and this is achieved by preventing recruitment of MED1, MED13L, and MED26 to the promoter.
PT-S264 augments NCOR binding to PPAR␤/␦
We previously found that depletion of NCOR by RNAi alleviates basal repression to the same extent as PPAR␤/␦ depletion but does not prevent repression by an inverse agonist (15) . However, RNAi-mediated partial depletion may not suffice for full loss of function, especially if the affinity of PPAR␤/␦ binding to NCOR is considerably high in the presence of an inverse agonist. To identify candidate repressors in an unbiased approach, ChIP-mass spectrometry (ChIP-MS) according to the RIME (rapid immunoprecipitation and mass spectrometry of endogenous proteins) protocol (45) was performed with an antibody against PPAR␤/␦. We used chromatin from MDA-MB231-luc2 cells, in which PPAR␤/␦ target gene repression by inverse agonists is particularly strong ( Supplementary Figure S2 and (15)). PPAR␤/␦ and RXR were robustly identified both in the presence of the inverse agonist PT-S264 and the agonist L165,041 (see Table 1 ). Importantly, NCOR (encoded by the NCOR1 gene) and SMRT (encoded by the NCOR2 gene) were identified as interactors only in the presence of PT-S264 but not in the presence of L165,041. Other known transcriptional repressors were not detected. The NCOR2 protein cluster revealed 15 and 7 unique peptides for NCOR after treatment with PT-S264 in the two technical replicates, while only 4 and 3 peptides were identified for SMRT. This finding may indicate that NCOR binding to PPAR␤/␦ is dominant over SMRT binding in MDA-MB231-luc2 cells in the presence of PT-S264. Of note, TBL1XR1, a subunit of NCOR and SMRT complexes (7) , was also only detected in the presence of PT-S264 but not in the presence of L165,041. Other NCOR and SMRT complex subunits such as HDAC3 were not detected. This could be due to insufficient sensitivity, the destructive nature of chromatin sample preparation, or both.
Next, we measured NCOR binding to the PPAR␤/␦ binding sites (PPREs) of the target genes ANGPTL4 and PDK4 (1) in MDA-MB231-luc2 cells in the presence and in the absence of PT-S264 by ChIP-qPCR using two differ- Protein kinase C␦-binding protein
The numbers indicate the mean unique peptide count from two technical replicates each. The difference count is peptides(PT-S264)-peptides(L165,041) for the cognate IPs (␣-PPAR␤/␦). An IgG fraction from non-immunized rabbits served as a negative control. The gene names of the antibody target (PPARD) and known interactors are printed in boldface. ent antibodies. In agreement with ChIP-MS data, NCOR is present at the ANGPTL4 PPREs. Interestingly, we find increased binding of NCOR after treatment with the inverse agonist PT-S264 both in the presence and in the absence of TGF␤ ( Figure 3A ). Further ChIP-qPCR analyses of several NCOR and SMRT complex subunits are in line with the ChIP-MS results, showing increased recruitment to the PPAR␤/␦ binding site of ANGPTL4 in the presence of PT-S264 and decreased recruitment in the presence of L165,041 ( Figure 3B ). This includes PT-S264-dependent recruitment of HDAC3, which is clearly expressed in these cells (15) .
In Caki-1 cells, ANGPTL4 expression is modulated by L165,041 and PT-S264 in the same manner as in MDA-MB231-luc2 cells; the amplitude of the effects is weaker in Caki-1, while expression in the basal state is considerably higher (Supplementary Figure S3 ). Increased NCOR recruitment to the ANGPTL4 PPREs is also observed in Caki-1 cells upon treatment with PT-S264 (Supplementary Figure S4 ). Due to its marked contribution to basal repression (15) and its enhanced recruitment to chromatinbound PPAR␤/␦ in the presence of PT-S264, we postulate that NCOR mediates downregulation of ANGPTL4 by 
Generation and characterization of PPAR␤/␦ knockout clones
To test whether NCOR is functionally important for PT-S264-mediated repression, we tried to disrupt NCOR expression through genetic deletion with the CRISPR-Cas9 system but were repeatedly unable to obtain NCOR knockout clones. We therefore aimed to disrupt NCOR binding to PPAR␤/␦ through mutations of the receptor as an alternative strategy. As a prerequisite for screening PPAR␤/␦ mutants, we introduced frameshift muta-tions to the PPARD coding region in MDA-MB231-luc2 cells using the CRISPR-Cas9 system. Four different PPAR␤/␦ knockout clones were isolated (2B2, 2B3, 2A3, 2A6; see Supplementary Figure S5A ). Neither PPAR␣ nor PPAR␥ expression was disrupted in the four clones ( Supplementary Figure S5B and C) . ChIP-qPCR confirmed the absence of PPAR␤/␦ at the ANGPTL4 and PDK4 loci (Figure 4 ). Interestingly, binding of PPAR␣ and PPAR␥ to the ANGPTL4 and PDK4 loci, each of which harbours three adjacent PPRE sequences (1, 12, 18) , is increased in PPAR␤/␦ knockout cells, suggesting that PPAR␣, PPAR␤/␦, and PPAR␥ compete for the same binding sites. However, relative to wild-type (WT) cells, binding of RXR is reduced in PPAR␤/␦ KO cells. This finding indicates that PPAR␤/␦ is the main factor that binds to the PPREs of the ANGPTL4 and PDK4 genes in MDA-MB231-luc2. Consistently, both induction of the ANGPTL4 transcript by the synthetic agonist L165,041 and repression by the inverse agonist PT-S264 were disrupted in the knockout clones (Supplementary Figure S6 ). In contrast, the PPAR␥ agonist pioglitazone retained its function and stimulated ANGPTL4 expression. Surprisingly (for unknown reasons), the PPAR␣ agonist Wy-14643 did not induce expression of the ANGPTL4 gene in the KO clones (Supplementary Figure S6 ).
Functional reconstitution of PPAR␤/␦ in knockout cells
In contrast to other PPAR␤/␦ knockout clones we obtained, the 2B3 clone neither showed growth defects, nor poor viability (observed in the 2A6 clone after several passages, data not shown), nor stable integration of the Cas9 expression vector (2B2, Supplementary Figure S5E ) or of the transiently transfected blasticidin resistance marker (2A3; Supplementary Figure S5F ). We therefore used the 2B3 clone for rescue experiments with expression vectors that encode for WT PPAR␤/␦. Sequencing of cloned PCR fragments indicates that guide RNAs 1 and 3 result in single-base deletions (no. 1) or insertions (no. 3; sequences from clone 2B3 are shown in Supplementary Figure S5G ). In line with previous observations (53) , ectopic expression of PPAR␤/␦ driven by the strong cytomegalovirus promoter led to formation of intracellular aggregates and failed to restore ligand function (data not shown). We stably transfected the 2B3 clone with a vector encoding the murine ecotropic retroviral receptor (42) , allowing for ecotropic retroviral infection. The resulting 2B3-ecoR cells were then transduced with pMSCV vectors to express WT or mutant PPAR␤/␦, driven by the comparably weak viral long terminal repeats. Expression of the mutants was confirmed on protein level (Supplementary Figure S7 ). We assume that PPAR␤/␦ is weakly expressed in all cellular models we analysed due to low signals on both RNA and protein levels. The level of PPAR␤/␦ ectopically expressed from pMSCV was above that of WT cells (Supplementary Figure S7) . Nevertheless, both the activation and repression functions of PPAR␤/␦ were restored, albeit to lesser extent than that observed in WT cells (Supplementary Figure S8 ).
A reconstitution screen identifies PPAR␤/␦ mutants deficient in ligand response and basal repression
Using PPAR␤/␦ knockout cells, it is possible to screen for mutants which are compromised in their repressive function. We generated a panel of 80 mutants that encode for truncated proteins or proteins with one or more substitutions of amino acid residues. We preferentially mutated residues at the surface of the LBD (ligand binding domain) since the LBD is involved in NCOR interactions (54) (55) (56) , and the affinity of corepressor-derived peptides to the PPAR␤/␦ LBD is enhanced by inverse agonists (5) . Published X-ray crystallography structural data of the PPAR␤/␦ LBD bound to an agonist (PDB ID: 3TKM (57)), the PPAR␣ LBD bound to an inverse agonist (PDB ID: 1KKQ (55)), and the PPAR␥ -RXR heterodimer (PDB ID: 3DZY (58)) were used as reference for choosing candidate residues. The panel also includes a negative control, C91A-E92A, a double mutant of residues critical for DNA binding (59) . This mutant should be defective in all functions of DNA-bound PPAR␤/␦ (basal repression, induction by agonist, repression by inverse agonist). We then performed a functional screen, intending to identify residues of PPAR␤/␦ which are necessary for basal and PT-S264regulated repression of the ANGPTL4 gene--mutations with functional consequences for either mode of repression should correspond to changes in NCOR binding if the effects are mediated by NCOR recruitment.
ANGPTL4 expression was monitored by RT-qPCR in the absence (after treatment with the solvent) or the presence of a ligand. As ligands, we used either the inverse agonist PT-S264 or the agonist L165,041. Importantly, the ligands did not modulate ANGPTL4 expression in PPAR␤/␦ knockout cells transduced with the empty vector or the DNA binding-deficient PPAR␤/␦ C91A-E92A mutant (Supplementary Figure S9 and Figure 5B ). An extended description of the screen is available in the Supplementary Material including expression data for all mutants (Supplementary Appendices A-D) and a simplified overview with a classification of the effect of each mutant ( Supplementary Table S3 ).
Briefly, our efforts identified several mutants which are generally compromised for receptor function, mutants which are compromised for ligand binding, mutants which show enhanced basal repression, and mutants which are deficient in basal repression. In this study, special interest pertains to mutants which affect repression. For visualization of effects on repression, we plotted the ratio of basal ANGPTL4 expression on the x-axis as Ct(basal WTbasal mutant); the Ct term is due to the use of " Ct" values normalized to the housekeeping transcript. This way, loss of repression is reflected in a positive value. Ct(PT-S264 WT-PT-S264 mutant) is plotted on the y-axis. The reconstituted WT receptor is at (0;0), and mutations which compromise both modes of repression cluster with the empty vector control in the upper right area of the graph ( Figure 5A ).
Mutants modified only in basal repression cluster on or below the x-axis ( Figure 5A ), whereas mutants with differential capability for PT-S264-dependent repression should cluster on the y-axis. We identified both kinds of mutants; however, deficiency in PT-S264-dependent repression was accompanied by loss of response to L165,041 in the few mutants we identified, indicating that the effect is not specific for the inverse agonist since ligand binding is compromised (see Supplementary Figure S9 ).
Strikingly, mutants with deficient basal repression (R314A, K421A-K422A, K421A, T427F, and T427I) show enhanced repression in the presence of PT-S264. These do not markedly deviate from the x-axis ( Figure 5 ), indicating that, while basal repression is compromised, PT-S264 is able to repress ANGPTL4 expression to similar levels as achieved in the presence of the WT receptor (see also Supplementary Figure S9 ). This implies that the observed fold repression is higher by the amount lost from basal repression (see below).
Conversely, in cells expressing mutants with enhanced basal repression (negative on the x-axis; I327A, T423A, T427D, and L433F), little or no PT-S264-stimulated repression was measured (Supplementary Figure S9) . Therefore, the mutations affecting basal repression we identified here as well as the inverse agonist itself presumably modulate the affinity of PPAR␤/␦ towards the same repressors. We however cannot rule out that mutants with enhanced basal repression recruit additional other repressors. Moreover, due to low ANGPTL4 expression levels in cells expressing these mutants, we are running into detection problems.
In the following experiments, we focus on three mutants with deficient basal repression, K421-K422A, T427I, and R314A. In Figure 5B , detailed ANGPTL4 RT-qPCR data for these three mutants are shown. Basal repression of ANGPTL4 is relieved in cells expressing these mutants, resulting in a higher fold repression in the presence of PT-S264, while fold induction by the agonist L165,041 is lowered. In the presence of the activating stimulus TGF␤, repression by PT-S264 is functional in cells expressing these mutants, albeit to an extent similar to cells transduced with WT PPAR␤/␦.
The main finding of the functional screen is that loss of basal repression is fully compensated for by the inverse agonist PT-S264, resulting in higher fold repression. Vice versa, enhanced basal repression limits repression by PT-S264. This leads to the hypothesis that the same corepressor(s) mediate both basal and inverse agonist-dependent repression. The K421A-K422A, T427I, and R314A mutants chosen for further analysis predominantly show PT-S264mediated repression and thus allow to investigate whether Nucleic Acids Research, 2019, Vol. 47, No. 18 9583 basal repression and PT-S264-dependent repression indeed depend on the same corepressor(s). Due to data obtained by mass spectrometry (Table 1) , we assume that repression is mediated by NCOR or both NCOR and SMRT.
PPAR␤/␦ mutants deficient in basal repression show diminished NCOR and SMRT recruitment to chromatin and increased RNA polymerase II recruitment in the basal state
We next asked if the mutants deficient in basal repression indeed show differential binding of NCOR and SMRT as predicted. To this end, we analysed a panel of four PPAR␤/␦ target genes at the chromatin level. Our previous genomewide studies identified PPAR␤/␦ binding sites and target genes in different cellular model systems (1, 2, 12, 15) including the MDA-MB231-luc2 cell line used here (15) . The genes strongly regulated by PPAR␤/␦ ligands in cell lines are ANGPTL4, PDK4, ABCA1, and PLIN2. ChIP-qPCR analyses reveal that binding of both NCOR and SMRT to PPAR␤/␦-responsive elements of the genes ANGPTL4, PDK4, and PLIN2 is markedly reduced in cells that express the T427I, K421A-K422A, and R314A mutants (Figure 6 ). However, in the presence of PT-S264, NCOR and SMRT binding is restored by the T427I, K421A-K422A, and R314A mutants. Essentially, the same observation was made for HDAC3 (Supplementary Figure S10) . As an additional control, the presence of mutated PPAR␤/␦ and RXR as well as NCOR recruitment by PT-S264 at the ANGPTL4 PPAR binding site was confirmed (Supplementary Figure S11 ). Moreover, in the absence of ligand, binding of RNAPII to the ANGPTL4, PDK4, PLIN2, and ABCA1 target gene TSSs is strongly reduced in PPARD KO cells reconstituted with WT PPAR␤/␦ ( Figure 7A -D) but not in cells expressing the T427I or K421A-K422A mutants. Strikingly, PT-S264 treatment leads to reduced RNAPII binding in cells expressing these mutants. Notably, the mode of ligand binding is not altered in the mutants since an additional mutation that occludes the ligand binding pocket abrogates ligand function (see Supplementary Figure S12 ). RNAPII binding at the TSS of TSC22D3, which is not a PPAR target gene, is neither affected by expression of the PPAR␤/␦-encoding cDNAs nor by PT-S264 ( Figure 7F ). This finding shows that the PPAR␤/␦ mutants deficient in basal NCOR, SMRT, and HDAC3 binding allow for increased RNAPII occupancy in the absence of activating ligands. Conversely, these mutants recruit NCOR, SMRT, and HDAC3 in the presence of the inverse agonist PT-S264, and thus RNAPII binding is strongly reduced. These observations indicate that NCOR and SMRT mediate both basal and PT-S264-dependent repression by limiting RNAPII binding to PPAR␤/␦ target genes. Strong reduction of RNAPII binding in cells expressing the T427I or K421A-K422A mutants upon short (30 min) treatment with PT-S264 strongly suggests that PPAR target genes other than ANGPTL4--PDK4, PLIN2, and ABCA1 are shown here--are also regulated at the level of initiation by PT-S264. We were however unable to reliably detect GTFs and Mediator subunits at these genes, which presumably is due to their comparably low expression (see Supplementary Figure S4 for ANGPTL4 in MDA-MB231-luc2) and limited sensitivity of the antibodies.
Additionally, we used samples obtained by treatment of Caki-1 cells with the initiation inhibitor triptolide and subjected to RNAPII ChIP (see Figure 1 ) to test whether PT-S264 mimicked the effect. Supplementary Figure S14 shows that RNAPII occupancy at the PLIN2 TSS is reduced even more strongly than at the ANGPTL4 TSS by PT-S264, while the effect is less pronounced at the ABCA1 TSS; the effect of triptolide is similar but stronger. Collectively, these results implicate that PT-S264 reduces RNAPII recruitment at PPAR target genes.
The role of deacetylase activity in repression by PT-S264
In order to investigate the role of the HDAC3 subunit of NCOR and SMRT complexes in repression of PPAR␤/␦ target genes, we treated cells with PT-S264 together with HDAC inhibitors. In WT MDA-MB231-luc2, neither TSA nor the HDAC3-selective compound apicidin abrogates repression of ANGPTL4 elicited by PT-S264 ( Figure 8A , upper left panel). However, repression of ANGPTL4 is diminished by the HDAC inhibitors. PT-S264-mediated repression of PDK4, which is weaker in comparison to ANGPTL4, is also diminished by the HDAC inhibitors ( Figure 8A , upper right panel), albeit to a lesser extent. Another PPAR␤/␦ target gene transcript, PLIN2, shows the same pattern ( Figure 8A, lower left panel) .
In KO cells with restored WT PPAR␤/␦ expression, PT-S264-mediated repression of ANGPTL4 is insensitive to the HDAC inhibitors, whereas in PPARD KO cells expressing mutants deficient in basal repression, repression of ANGPTL4 by PT-S264 is partially sensitive to HDAC inhibition ( Figure 8B ). The PDK4 transcript is affected similarly. This clearly suggests that the NCOR and SMRT complexes recruited to PPAR␤/␦ target genes exert both deacetylase-dependent and deacetylase-independent repressive functions; the catalytic activity of HDAC3 contributes to but is not sufficient for full repression. This is in agreement with the observation that ANGPTL4 expression is only weakly induced by HDAC inhibitors (Figure 8B and (15)).
In general, weaker repression in 2B3 cells reconstituted with the WT PPARD cDNA relative to the parental cells was observed (Supplementary Figure S6) . We attribute this to sequestration of corepressors by overexpressed WT PPAR␤/␦, which recruits NCOR and SMRT considerably stronger than the mutants deficient in basal repression (Figure 6 ). Sequestration might differentially affect the availability of free NCOR and SMRT.
DISCUSSION
NCOR and SMRT figure in gene regulation by a multitude of transcription factors such as the glucocorticoid receptor (60, 61) , other nuclear receptors (6, 62) , POZ-containing, basic helix-loop-helix and basic leucine zipper factors (63) , the Notch effector RBP-J (64), and MECP2 (methylated CpG binding protein 2) (65). Therefore, elucidation of regulatory mechanisms used by NCOR and SMRT complexes is of great interest. We show here that PPAR␤/␦ inverse agonists interfere with recruitment of the transcription-permissive Mediator subunits MED1, MED13L, and MED26 as well as TFIIB and RNAPII. PPAR␤/␦ mutants deficient in NCOR and SMRT recruitment in the basal state allow for enhanced RNAPII binding in the absence of ligands, while the inverse agonist PT-S264 restores both NCOR and SMRT binding to these mutants and loss of RNAPII at target gene promoters. Repression is only partially sensitive to HDAC inhibition, which indicates that NCOR/SMRT complexes exert deacetylase-dependent and deacetylase-independent functions to restrain transcription of PPAR␤/␦ target genes.
HDAC-independent repression mechanisms exerted by NCOR/SMRT have also been reported in other contexts: (i) In mice, Ncor and Smrt complexes carry out essential functions that are independent of Hdac3 activity (66) , and (ii) HDAC-independent repression of human papillomavirus transcription and replication by NCOR was demonstrated (67) . (iii) Finally, whereas MECP2 represses transcription via an HDAC-independent mechanism (68), interaction with NCOR/SMRT is crucial for MECP2 function (65) , and it was reported recently that the detrimental Significance levels were calculated via paired t-tests. **** , P < 0.0001; *** , P < 0.001; ** , P < 0.01; * , P < 0.05; n.s., not significant. effects of Mecp2 overexpression in mice do not depend on the catalytic activity of Hdac3 (69) .
Our data suggest that deacetylation by HDAC3 contributes to but is not sufficient for basal repression of PPAR␤/␦ target genes. Thus, an additional enzymatic function of HDAC3-containing complexes or, alternatively, inhibition of an activator-borne enzymatic activity may be required for efficient silencing of gene expression. We speculate that acetyltransferases are inhibited by NCOR and SMRT complexes since (i) acetyltransferase activity is required for transcription in nucleosome-free systems (70), (ii) GTFs that contribute to reinitiation--TFIIB, TFIIE, and TFIIF--are acetylated in vivo (71, 72) , and (iii) the acetyltransferase activities of CBP and p300 are inhibited by recombinant purified fragments of NCOR and SMRT in vitro (73, 74) . Moreover, Mediator interacts with the acetyltransferase-bearing SAGA complex, and both Mediator and SAGA are necessary for RNAPII-mediated transcription in yeast (75) (76) (77) . Partial sensitivity of PT-S264-dependent repression to HDAC inhibitors ( Figure 8 ) strongly suggests that NCOR and SMRT recruited by PPAR␤/␦ use an additional mechanism to restrict activator function. It is striking that, in cells ectopically expressing PPAR␤/␦ mutants with deficient basal repression, PT-S264-dependent repression is more sensitive to HDAC inhibition than in cells ectopically expressing the WT receptor ( Figure 8B ). This finding suggests that the NCOR/SMRT complexes involved in basal repression, whose binding is restored by PT-S264 in cells expressing the mutants (Figure 6) , rely on HDAC activity to a larger extent compared to the complexes that are recruited to the WT receptor upon treatment with PT-S264.
Induction of the PPAR␤/␦ target gene ANGPTL4 by TGF␤ depends on SMAD3 (18) , which interacts with CBP and p300 to activate transcription (78) . CBP and p300 are also paramount coactivators of NFB (79) and AP-1 (80) transcription factors, which are major targets of transrepression by nuclear receptors (61, (80) (81) (82) . These data underscore a possible role for acetyltransferase inhibition in gene regulation by NCOR and SMRT. Since deacetylation and inhibition of acetyltransferase activity act towards the same outcome, the two functions may conceivably act in parallel for more efficient suppression of transcription. Another possibility would be that ubiquitin ligase and deubiquitinase activities which reside in subunits of HDAC3-containing complexes contribute to deacetylaseindependent repression. Ubiquitination by TBLR1 (6) could commit activators for degradation, or H2B deubiquitination by USP44 might figure in repression of ANGPTL4 by NCOR/SMRT (36) .
Mediator supports TFIIB binding to promoters, and both Mediator and TFIIB facilitate recruitment of RNAPII to promoter-bound GTFs (30) . This notion is in agreement with both older and more recent studies in yeast (47, 75, 83, 84) , murine (85) , and human cells (86) which indicate concurrent interactions of Mediator, TFIIB, and RNAPII. MS data from S. cerevisiae and from human cells identify RNAPII, TFIIB, and TFIIF amongst the strongest interactors of Mediator (75, 86) , and these factors are necessary for reinitiation (25) . Notably, another recent study revealed that human genes which require de novo RNAPII recruitment for induction of transcription depend on TFIIB availability (87) . It is unclear how transcription factors modulate reinitiation, and in vivo evidence of reinitiation and scaffold complexes is lacking (32) . Our ChIP data (Figure 1 and Supplementary Figure S2 ), which demonstrate impairment of TFIIB and RNAPII binding by PPAR␤/␦ inverse agonists, are in agreement with findings obtained from in vitro systems that describe recruitment of RNAPII and TFIIB (25, 30) to scaffold factors and thus may represent in vivo correlates of reinitiation and scaffold complexes. RNAPII binding to the ANGPTL4 promoter is affected similarly by PT-S264 and the TFIIH-XPB inhibitor (88) triptolide ( Figure 1A) ; triptolide is expected to affect both initiation and reinitiation. Our ChIP data do not allow for discrimination between the first and subsequent rounds of transcription; hence, we cannot conclude whether the first round of transcription is affected as well.
Our observations furthermore suggest that TFIIB and RNAPII recruitment coincides with the presence of MED1, MED13L, and MED26 ( Figure 2 ). This notion is supported by previous work of others which identified MED1 (48, 49) , MED13L (52), and MED26 (52, 89, 90) as subunits that are predominantly present in RNAPII-associated Mediator. Our observations are compatible with the model that the MED13-containing kinase module blocks RNAPII association with Mediator (31) since MED26 and MED13 binding is mutually exclusive (52) . Notably, co-occurrence of MED13L and MED26 was described (48, 52, 89, 90) . Our model thus favours an RNAPII-associated Mediator state which harbours the MED1, MED13L, and MED26 subunits, and this is counteracted by PT-S264 at PPAR␤/␦ target genes.
It should be noted that we cannot formally exclude involvement of corepressors other than NCOR and SMRT in PT-S264-dependent repression. Genetic deletion of NCOR1 was unsuccessful in our hands; this is consistent with the notions that NCOR function may be necessary for regulation of the cell cycle (91), genome stability (92), or other critical processes (62) . Cellular models without this limitation or knock-in approaches might be suitable to resolve whether NCOR and SMRT complexes are sufficient for repression by PPAR␤/␦ inverse agonists. Modification of endogenous coding sequences would also circumvent possible effects of overexpression such as cofactor sequestration. Notably, after reconstitution of PPAR␤/␦ expression, PT-S264-dependent repression is largely insensitive to HDAC inhibition, which is in contrast to partial sensitivity observed in the parental cell line. Moreover, HDAC inhibition leads to weaker upregulation of PPAR␤/␦ target genes in the parental cells compared to cells with reconstituted PPAR␤/␦. This could be due to higher recruitment of SMRT relative to recruitment of NCOR after reconstitution of PPAR␤/␦ expression ( Figure 6 ), whereas the ratio of ChIP-qPCR signals obtained with the same antibodies is closer to one in WT cells (Figure 3 ). However, the preferential dependence of SMRT complexes on deacetylase activity relative to NCOR complexes is highly speculative.
Taken together, we propose that PPAR␤/␦ recruits NCOR and SMRT, either of which or both block MED1, MED13L, and MED26 recruitment to promoter-bound GTFs via both deacetylase-dependent and -independent . Ligand-dependent regulation of ANGPTL4 transcription initiation by PPAR␤/␦ and NCOR/SMRT. Data from this study show that the PPAR␤/␦ inverse agonist PT-S264 interferes with activator-stimulated recruitment of MED1, MED13L, MED26, TFIIB, and RNAPII. Mutations of PPAR␤/␦ which abrogate NCOR and SMRT binding in the basal state allow for increased binding of RNAPII, and NCOR and SMRT binding is restored upon addition of PT-S264. The latter observations were made at other PPAR target genes as well. Taken together with our previous observation that synthetic PPAR agonists together with other activating stimuli synergistically induce ANGPTL4 transcription (18), we propose the model that basal and ligand-dependent repressor recruitment limit the ability of activators to induce transcription reinitiation (and possibly initiation) via NCOR, SMRT, or both. The corepressors use both deacetylase-dependent and deacetylase-independent mechanisms, the latter of which are not elucidated as of now.
functions to interfere with TFIIB and RNAPII binding. A model depicted in Figure 9 summarizes our conclusions. Additional insight will require identification of the subunits and domains of NCOR and SMRT complexes which exert deacetylase-independent repression and their target proteins, and it will be interesting to probe possible differential functions of NCOR and SMRT.
